Biogen Idec Inc. and Elan Corp. plc reported two new cases of PML — though not much else, to the chagrin of investors and analysts — linked to multiple sclerosis therapy Tysabri (natalizumab), spoiling the controversial drug's two-year anniversary of its re-launch onto the market. (BioWorld Today) Read More
